Breaking News Instant updates and real-time market news.

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

, RHHBY

Roche

$0.00

(0.00%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07

Voyager Therapeutics names Robert Hesslein as general counsel

Voyager Therapeutics (VYGR) announced the appointment of Robert Hesslein as general counsel. Hesslein expects to begin working at Voyager in early April. Hesslein is joining Voyager from Foundation Medicine, which was acquired by Roche (RHHBY) in July 2018, where he served as senior vice president, general counsel and chief compliance officer since 2012, responsible for managing corporate governance and all legal matters related to Foundation Medicine's business including commercial, corporate and business development, compliance, and research and development functions.

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

RHHBY

Roche

$0.00

(0.00%)

  • 28

    Jan

  • 01

    Feb

  • 18

    Mar

VYGR Voyager Therapeutics
$8.27

-0.22 (-2.59%)

01/08/19
BTIG
01/08/19
NO CHANGE
Target $23
BTIG
Buy
Voyager Therapeutics price target lowered to $23 from $32 at BTIG
BTIG analyst Thomas Shrader lowered his price target on Voyager Therapeutics to $23 after the company's announcement yesterday about increasing the size of its RESTORE-1 Phase 2 trial for VY-AADC in Parkinson's Disease following FDA feedback. The analyst notes that the "final answer" on the trial represents "about a year delay" in the development of VY-ADCC, but keeps his Buy rating on the stock, saying he remains positive on Voyager Therapeutics investment story.
11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/18
RAJA
11/14/18
UPGRADE
RAJA
Strong Buy
Voyager Therapeutics upgraded to Strong Buy from Outperform at Raymond James
11/09/18
HCWC
11/09/18
NO CHANGE
Target $25
HCWC
Buy
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Voyager Therapeutics to $25 after the company received an addendum from the FDA indicating that the agency currently considers the Phase 2 as an exploratory study. Given the limited clinical catalysts for the stock and the significant management turnover during 2018, "the latest headwind was not well received by the Street in our view," Chattopadhyay tells investors in a research note. He keeps a Buy rating on the shares.
RHHBY Roche
$0.00

(0.00%)

01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
12/20/18
PIPR
12/20/18
NO CHANGE
Target $400
PIPR
Overweight
Survey shows 'solid fundamentals' for Biogen MS franchise, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Biogen (BIIB) with a $400 price target after surveying 100 neurologists. The survey feedback shows "solid fundamentals" for the company's multiple sclerosis portfolio, Raymond tells investors in a research note. He admits, however, that many investors are preoccupied with Tecfidera's intellectual property situation. Nonetheless, neurologists reported meaningful share gains for Tecfidera and Tysabri this quarter, says the analyst. Raymond believes worries over the impact to Biogen's multiple sclerosis franchise from Roche's (RHHBY) Ocrevus launch "may be behind us."
12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
12/17/18
PIPR
12/17/18
NO CHANGE
PIPR
Proteostasis deal with Genentech strenghtens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Proteostasis (PTI), noting the company announced an agreement with Roche's (RHHBY) Genentech to license small molecule modulators of an undisclosed target that lie outside of Cystic Fibrosis, which makes the company eligible for $100M in upfront and milestone payments plus royalties. Tenthoff sees this deal strengthening Proteostasis' balance sheet. Additionally, Tenthoff is optimistic on Proteostasis' TripleRx combo, and expects full Phase I TripleRx data in Q1 of 2019. Longer term, the analyst anticipates TripleRx approval in 2021, with global sales of $2.0B by 2026.

TODAY'S FREE FLY STORIES

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

PLNT

Planet Fitness

$66.76

-0.825 (-1.22%)

18:44
03/22/19
03/22
18:44
03/22/19
18:44
Hot Stocks
Planet Fitness CEO: We have a streamlined business model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRDM

Iridium

$26.40

-0.38 (-1.42%)

18:22
03/22/19
03/22
18:22
03/22/19
18:22
Hot Stocks
Iridium CEO: We've doubled our bottom line over the past eight years »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:05
03/22/19
03/22
18:05
03/22/19
18:05
General news
Sen. Sanders calls on White House to make Mueller report public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

, RNECY

Renesas

$0.00

(0.00%)

18:02
03/22/19
03/22
18:02
03/22/19
18:02
Hot Stocks
Integrated Device, Renesas receive final approval for merger »

Renesas Electronics…

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

RNECY

Renesas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:48
03/22/19
03/22
17:48
03/22/19
17:48
General news
Senator Warren urges AG Barr to release Mueller report to the public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
Lawmaker urges FAA, Boeing workers to utilize whistleblower page »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

GLD

SPDR Gold Shares

$123.97

0.29 (0.23%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
SPDR Gold Shares holdings rise to 781.03MT from 778.09MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:40
03/22/19
03/22
17:40
03/22/19
17:40
General news
Weekly CFTC Commitment of Traders highlights »

10-YEAR U.S. TREASURY net…

ONEXF

Onex

$0.00

(0.00%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Onex to acquire Gluskin Sheff »

Onex Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

REPH

Recro Pharma

$9.73

0.1 (1.04%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Breaking Hot Stocks news story on Recro Pharma »

Recro Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Mar

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:34
03/22/19
03/22
17:34
03/22/19
17:34
General news
White House says hasn't received, been briefed on Mueller report, WSJ says »

Following confirmation…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATS

Catasys

$13.19

-0.39 (-2.87%)

17:26
03/22/19
03/22
17:26
03/22/19
17:26
Syndicate
Breaking Syndicate news story on Catasys »

Catasys files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USWS

U.S. Well Services

$7.74

-0.54 (-6.52%)

17:20
03/22/19
03/22
17:20
03/22/19
17:20
Syndicate
Breaking Syndicate news story on U.S. Well Services »

U.S. Well Services files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADIL

Adial Pharmaceuticals

$2.97

-0.12 (-3.88%)

17:17
03/22/19
03/22
17:17
03/22/19
17:17
Syndicate
Breaking Syndicate news story on Adial Pharmaceuticals »

Adial Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNG

Scorpio Tankers

$18.85

-0.66 (-3.38%)

17:16
03/22/19
03/22
17:16
03/22/19
17:16
Syndicate
Breaking Syndicate news story on Scorpio Tankers »

Scorpio Tankers files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.14

-0.0001 (-0.07%)

17:13
03/22/19
03/22
17:13
03/22/19
17:13
Syndicate
Navidea offers to sell $3M in common stock for existing shareholder »

Navidea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:11
03/22/19
03/22
17:11
03/22/19
17:11
General news
Mueller delivers Russia report to AG William Barr, CNBC reports »

Special counsel Robert…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

, NOC

Northrop Grumman

$268.29

-4.01 (-1.47%)

17:10
03/22/19
03/22
17:10
03/22/19
17:10
Hot Stocks
Boeing awarded $4.14B Missle Defense Agency contract »

Boeing (BA) has been…

BA

Boeing

$362.49

-10.2 (-2.74%)

NOC

Northrop Grumman

$268.29

-4.01 (-1.47%)

RTN

Raytheon

$179.98

-1.94 (-1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

AAPL

Apple

$190.97

-4.1 (-2.10%)

17:09
03/22/19
03/22
17:09
03/22/19
17:09
Periodicals
Partners not sure how Apple plans to package, price video service, CNBC says »

Apple is set to announce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

RIVE

Riverview Financial

$11.20

(0.00%)

17:05
03/22/19
03/22
17:05
03/22/19
17:05
Syndicate
Breaking Syndicate news story on Riverview Financial »

Riverview Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIVE

Riverview Financial

$11.20

(0.00%)

17:05
03/22/19
03/22
17:05
03/22/19
17:05
Syndicate
Breaking Syndicate news story on Riverview Financial »

Riverview Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.